GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alaunos Therapeutics Inc (NAS:TCRT) » Definitions » E10

Alaunos Therapeutics (Alaunos Therapeutics) E10 : $-7.54 (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Alaunos Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Alaunos Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was $-0.490. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-7.54 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average E10 Growth Rate was 10.10% per year. During the past 5 years, the average E10 Growth Rate was 6.70% per year. During the past 10 years, the average E10 Growth Rate was 24.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Alaunos Therapeutics was 61.80% per year. The lowest was 1.70% per year. And the median was 10.10% per year.

As of today (2024-04-27), Alaunos Therapeutics's current stock price is $1.32. Alaunos Therapeutics's E10 for the quarter that ended in Dec. 2023 was $-7.54. Alaunos Therapeutics's Shiller PE Ratio of today is .


Alaunos Therapeutics E10 Historical Data

The historical data trend for Alaunos Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alaunos Therapeutics E10 Chart

Alaunos Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.96 -10.37 -9.77 -8.31 -7.54

Alaunos Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.31 -8.22 -7.94 -7.67 -7.54

Competitive Comparison of Alaunos Therapeutics's E10

For the Biotechnology subindustry, Alaunos Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alaunos Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alaunos Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Alaunos Therapeutics's Shiller PE Ratio falls into.



Alaunos Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Alaunos Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.49/129.4194*129.4194
=-0.490

Current CPI (Dec. 2023) = 129.4194.

Alaunos Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201403 -1.500 99.695 -1.947
201406 -0.900 100.560 -1.158
201409 -0.900 100.428 -1.160
201412 -1.350 99.070 -1.764
201503 -10.350 99.621 -13.446
201506 -1.650 100.684 -2.121
201509 -2.100 100.392 -2.707
201512 -1.050 99.792 -1.362
201603 -1.350 100.470 -1.739
201606 -15.150 101.688 -19.282
201609 -1.650 101.861 -2.096
201612 -1.650 101.863 -2.096
201703 -2.250 102.862 -2.831
201706 -1.950 103.349 -2.442
201709 -1.950 104.136 -2.423
201712 -1.950 104.011 -2.426
201803 -2.250 105.290 -2.766
201806 -1.800 106.317 -2.191
201809 -1.950 106.507 -2.370
201812 19.350 105.998 23.626
201903 -1.200 107.251 -1.448
201906 -1.350 108.070 -1.617
201909 -6.450 108.329 -7.706
201912 -1.350 108.420 -1.611
202003 -1.350 108.902 -1.604
202006 -1.350 108.767 -1.606
202009 -1.500 109.815 -1.768
202012 -1.650 109.897 -1.943
202103 -1.500 111.754 -1.737
202106 -1.650 114.631 -1.863
202109 -1.650 115.734 -1.845
202112 -0.750 117.630 -0.825
202203 -0.750 121.301 -0.800
202206 -0.750 125.017 -0.776
202209 -0.600 125.227 -0.620
202212 -0.600 125.222 -0.620
202303 -0.600 127.348 -0.610
202306 -0.600 128.729 -0.603
202309 -0.600 129.860 -0.598
202312 -0.490 129.419 -0.490

Add all the adjusted EPS together and divide 10 will get our e10.


Alaunos Therapeutics  (NAS:TCRT) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Alaunos Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Alaunos Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Alaunos Therapeutics (Alaunos Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
8030 El Rio Street, Houston, TX, USA, 77054
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens (neoAg) arising from genomic mutations.
Executives
Boyle Kevin S. Sr. director, officer: Chief Executive Officer C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Robert Hofmeister director C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Jaime Vieser director ONE FIRST AVENUE, PARRIS BUILDING 34, NAVY YARD PLAZA, BOSTON MA 02129
Robert W Postma director 141 MECOX ROAD, WATER MILL NY 11976
Michael Wong officer: VP, Finance C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BUILDING #34, BOSTON MA 02129
Abhishek K Srivastava officer: See Remarks C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054
Holger Weis director C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Christopher Bowden director 38 SIDNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139
Mary Thistle director C/O VIACELL, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
James Huang director 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Drew Deniger officer: VP, Research & Development C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054
Groot Eleanor De officer: EVP, Operations C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Melinda Lackey officer: Senior Vice President, Legal C/O ZIOPHARM ONCOLOGY INC., 8030 EL RIO ST, HOUSTON TX 77054
Heidi Hagen director AASTROM BIOSCIENCES, INC., 24 FRANK LLOYD WRIGHT DRIVE, ANN ARBOR MI 48105
Raffaele Baffa officer: Chief Medical Officer C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129